{4-[(2S)-2-({[(3-aminophenyl)methoxy]carbonyl}amino)-2-[(1-{[(6S)-6-carbamoylcyclohex-2-en-1-yl]carbamoyl}cyclohexyl)carbamoyl]ethyl]phenoxy}phosphonic acid

ID: ALA1160046

PubChem CID: 44286626

Max Phase: Preclinical

Molecular Formula: C31H40N5O9P

Molecular Weight: 657.66

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: NC(=O)[C@H]1CCC=CC1NC(=O)C1(NC(=O)[C@H](Cc2ccc(OP(=O)(O)O)cc2)NC(=O)OCc2cccc(N)c2)CCCCC1

Standard InChI: InChI=1S/C31H40N5O9P/c32-22-8-6-7-21(17-22)19-44-30(40)35-26(18-20-11-13-23(14-12-20)45-46(41,42)43)28(38)36-31(15-4-1-5-16-31)29(39)34-25-10-3-2-9-24(25)27(33)37/h3,6-8,10-14,17,24-26H,1-2,4-5,9,15-16,18-19,32H2,(H2,33,37)(H,34,39)(H,35,40)(H,36,38)(H2,41,42,43)/t24-,25?,26-/m0/s1

Standard InChI Key: YENDXPUMHXTISG-ZURQMKNRSA-N

Molfile:

     RDKit          2D

 46 49  0  0  0  0  0  0  0  0999 V2000
    6.8625   -7.2042    0.0000 P   0  0  0  0  0  0  0  0  0  0  0  0
    7.7125   -2.8542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5667   -2.4417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8500   -2.4375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9917   -2.4417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2792   -2.8542    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.4250   -2.4417    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.1417   -2.8542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4250   -2.8625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8417   -1.6125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8542   -2.8625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1375   -2.4500    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.0417   -8.0417    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.2667   -7.7667    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.4750   -6.5292    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.6875   -7.0042    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.7125   -3.6792    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.5667   -1.6167    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.1375   -3.6792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8542   -3.6875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4250   -3.6875    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.1250   -1.2042    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.7042   -2.4500    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.8542   -4.0875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.5542   -1.1917    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.0667   -5.8167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2625   -4.4000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2792   -1.6250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5625   -1.2125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9917   -2.8667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5542   -0.3875    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.2792   -2.4542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8417   -5.1042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0750   -4.4000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4792   -5.1042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2500   -5.8125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.5625   -2.8417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9250   -1.7750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4667   -1.7625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1500   -2.4542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.5667   -3.6750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1500   -1.6250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5625   -2.8667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7917   -1.1167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2250   -1.0917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6917   -0.4042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  5  1  0
  3 11  1  0
  4  8  1  0
  5  6  1  0
  6  3  1  0
  7  2  1  0
  7  8  1  0
  9 12  1  0
  4 10  1  1
 11 20  1  6
 12 11  1  0
 13  1  1  0
 14  1  1  0
 15  1  1  0
 16  1  2  0
 17  2  2  0
 18  3  2  0
 19  8  1  0
 20 27  1  0
 21  9  2  0
 22 10  2  0
 23  9  1  0
 24 19  2  0
 25 10  1  0
 26 15  1  0
 27 33  2  0
 28 32  1  0
 29 28  2  0
 30 23  1  0
 31 29  1  0
 32 30  1  0
 33 36  1  0
 34 35  2  0
 35 26  1  0
 36 26  2  0
 37  4  1  0
 38  5  1  0
 39  5  1  0
 40 43  1  0
 41 24  1  0
 42 40  2  0
 43 32  2  0
 44 39  1  0
 45 38  1  0
 46 44  1  0
 27 34  1  0
 46 45  1  0
 42 29  1  0
 41 37  1  0
M  END

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Small molecule	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 657.66	Molecular Weight (Monoisotopic): 657.2564	AlogP: 2.33	#Rotatable Bonds: 12
Polar Surface Area: 232.40	Molecular Species: ACID	HBA: 8	HBD: 7
#RO5 Violations: 2	HBA (Lipinski): 14	HBD (Lipinski): 9	#RO5 Violations (Lipinski): 3
CX Acidic pKa: 1.78	CX Basic pKa: 4.01	CX LogP: 1.68	CX LogD: -1.13
Aromatic Rings: 2	Heavy Atoms: 46	QED Weighted: 0.10	Np Likeness Score: -0.08

References

1. Toogood PL.. (2002) Inhibition of protein-protein association by small molecules: approaches and progress., 45 (8): [PMID:11931608] [10.1021/jm010468s]
2. Yao, Z J ZJ and 6 more authors. 1999-01-14 Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. [PMID:9888830]
3. Ettmayer, P P and 10 more authors. 1999-03-25 Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2(1). [PMID:10090780]
4. Furet, P P and 5 more authors. 1999-07-01 Structure-based design, synthesis, and X-ray crystallography of a high-affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic. [PMID:10395476]
5. Gao, Y Y and 8 more authors. 2000-03-09 Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic. [PMID:10715157]
6. Lee, Kyeong K, Zhang, Manchao M, Liu, Hongpeng H, Yang, Dajun D and Burke, Terrence R TR. 2003-06-19 Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides. [PMID:12801226]
7. Song, Yan-Li YL, Roller, Peter P PP and Long, Ya-Qiu YQ. 2004-06-21 Development of l-3-aminotyrosine suitably protected for the synthesis of a novel nonphosphorylated hexapeptide with low-nanomolar Grb2-SH2 domain-binding affinity. [PMID:15149676]
8. Song, Yan-Li YL and 5 more authors. 2006-03-09 Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives. [PMID:16509576]
9. Jiang, Sheng S and 8 more authors. 2009-05-15 Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity. [PMID:19362470]

{4-[(2S)-2-({[(3-aminophenyl)methoxy]carbonyl}amino)-2-[(1-{[(6S)-6-carbamoylcyclohex-2-en-1-yl]carbamoyl}cyclohexyl)carbamoyl]ethyl]phenoxy}phosphonic acid

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source